| Name | Title | Contact Details |
|---|
Headquartered in the heart of Silicon Valley, California, VitalConnect was founded in 2011 with a vision of changing the paradigm of healthcare as we know it by creating a new world of information with predictive data analytics at everyone’s fingertips. VitalConnect provides physicians, nurses and patients with an extraordinary advancement in healthcare. Never before has so much continuous monitoring of vital signs been possible in a single, small—yet powerful—device. By consolidating eight critical vital signs into one wireless biosensor, VitalPatch enables a new view into healthcare, but more importantly it connects all interested parties in a patient’s recovery with each other. VitalConnect is also engaged in numerous partnerships with other leading medical device and pharmaceutical companies. It`s all about helping to bring a new paradigm and vision to fruition and providing the healthcare industry with the predictive data analytics it needs to reduce expenses, increase efficiency, provide better care—and most important of all, to save lives.
Peer Review Mediation and Arbitration is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Potrero Medical is a predictive health company that is developing the next generation of smart sensors and artificial intelligence.
Sandhill Scientific is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack